The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Uveitis: A Brief Primer for the Rheumatologist

Uveitis: A Brief Primer for the Rheumatologist

November 12, 2020 • By Meghan Berkenstock, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
This external photograph of the right eye shows keratic precipitates on the corneal endothelium, corneal edema and hemorrhagic hypopyon in the setting of acute herpetic anterior uveitis.

Figure 2. This external photograph of the right eye shows keratic precipitates on the corneal endothelium, corneal edema and hemorrhagic hypopyon in the setting of acute herpetic anterior uveitis.

Uveitis is an umbrella term for intraocular inflammatory diseases that can lead to vision loss. It’s not just a concern for ophthalmologists. Uveitis occurs in approximately 2–5% of patients with inflammatory bowel disease, 6–9% of patients with psoriatic arthritis and 25% of patients with reactive arthritis. The prevalence may be as high as 33% in patients with ankylosing spondylitis.1 Thus, it’s important rheuma­tologists have an understanding of this potentially debilitating condition.

You Might Also Like
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
  • Treating Uveitis with Adalimumab Improves Quality of Life
  • Pediatric Uveitis in the Biologic Age: Risk Factors, Treatment & Outcomes
Explore This Issue
November 2020

The Basics

Sandwiched between the dense connective tissue of the sclera externally and the neuro­sensory retina internally, the uvea comprises the pigmented, middle layer of the eye. Composed of the iris, ciliary body and choroid, inflammation within these structures is collectively called uveitis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The heterogeneous causes of uveitis include trauma, autoimmune disorders, infections, drug reactions and malig­nancies. When a cause is not identified, which occurs in approximately half of cases, the term idiopathic is used.

Intraocular inflammation is uncommon, with an estimated incidence of 26–52 cases per 100,000 people per year due to ocular immune privilege—the phenomenon in which the eye attempts to limit local immune and inflammatory responses to preserve vision.2,3 The eye lacks lymphatic drainage, and the aqueous humor contains immunosuppressive factors, including TGF-β.4 Additionally, intra­ocular tissues express Fas ligand, which promotes leukocyte apoptosis.4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Classifications

Intraocular inflammation is classified on the basis of anatomic location using the standardization of uveitis nomenclature (SUN):5

  • Anterior uveitis accounts for 50–90% of cases of ocular inflammation.6 It refers to inflammation of the iris or ciliary body with the focus of inflammation centered in the anterior chamber. Previous terms for anterior uveitis include iritis, iridocyclitis or anterior cyclitis.
  • Intermediate uveitis and posterior uveitis occurs in the posterior chamber. Intermediate uveitis describes inflammation within the vitreous body, which includes pars planitis or posterior cyclitis.
  • Posterior uveitis refers to inflammation predominately in the retina or choroid, and encompasses entities such as retinal vasculitis or neuroretinitis.
  • Finally, panuveitis occurs when inflammation is evenly distributed throughout the eye and not restricted to one chamber.

Uveitis can also be classified by onset or course.6 Although the onset of uveitis can be either sudden or insidious, the course denotes the duration.

Cystoid macular edema is seen on optical coherence tomography. The hyporeflective spaces within the retina represent fluid accumulation due to inflammatory vascular leakage. This is most common cause of vision loss in patients with uveitis.

Cystoid macular edema is seen on optical coherence tomography. The hyporeflective spaces within the retina represent fluid accumulation due to inflammatory vascular leakage. This is most common cause of vision loss in patients with uveitis.

Acute uveitis describes inflammation occurring for less than six weeks with sudden onset. If inflammation resolves, treatment is stopped, but if it occurs again after three months, the uveitis is considered recurrent. If there is less than three months of inactivity and lack of a treatment-free interval between episodes of inflammation, the uveitis is considered chronic.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Uncontrolled, chronic inflammation causes structural complications leading to blindness, including macular edema, cataracts, glaucoma or neovascularization of the retina.7

As the cause of 10–15% of blindness in the U.S. and Europe, uveitis and associated complications predominately affect patients during their working years. This leads to significantly more lost wages, increased medical costs and increased rates of disability compared to age-matched peers.8-10 Thus, rapid and continued control of intraocular inflammation is required.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions Tagged With: UveitisIssue: November 2020

You Might Also Like:
  • Aggressive Treatment of Inflammation Prevents Vision Loss in Patients with JIA-related Uveitis
  • Treating Uveitis with Adalimumab Improves Quality of Life
  • Pediatric Uveitis in the Biologic Age: Risk Factors, Treatment & Outcomes
  • Ankylosing Spondylitis & Uveitis: An Ophthalmologist’s Perspective

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)